Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives

Diagnostics

Volumn 7, Issue 1, 2017, Pages

  Subbiah, Vivek ^a   Chuang, Hubert H ^a   Gambhire, Dhiraj ^b   Kairemo, Kalevi ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

EASL; IrRC; MDA criteria; MRECIST; PERCIST; RANO criteria; RECICL; RECIST; WHO criteria

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYTOSTATIC AGENT; FLUORODEOXYGLUCOSE F 18; IMATINIB; NILOTINIB; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; REGORAFENIB; SUNITINIB;

ADULT; ADVANCED CANCER; AGED; ANATOMIC LANDMARK; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL RESEARCH; COMPUTER ASSISTED TOMOGRAPHY; DATA MINING; DISSEMINATED CANCER; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE CORE 30; EWING SARCOMA; FEMALE; FUNCTIONAL ASSESSMENT RESPONSE CRITERIA; GASTROINTESTINAL STROMAL TUMOR; GLIOMA; GROWTH; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; INFORMATION RETRIEVAL; LEUKEMIA; LIVER CELL CARCINOMA; MALE; MEDICAL RECORD REVIEW; MEDLINE; METABOLISM; METASTATIC BREAST CANCER; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY; PERSONALIZED MEDICINE; PET RESPONSE CRITERIA IN SOLID TUMORS; PLEURA MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RADIOMICS; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SARCOMA; SCLEROSIS; SOFT TISSUE SARCOMA; STANDARDIZATION; TUMOR VOLUME;

EID: 85084513645     PISSN: None     EISSN: 20754418     Source Type: Journal    
DOI: 10.3390/diagnostics7010010     Document Type: Article

References (43)

1. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment; World Health Organization: Geneva, Switzerland, 1979.
2. Green, S.; Weiss, G.R. Southwest oncology group standard response criteria, endpoint definitions and toxicity criteria. Investig. New Drugs 1992, 10, 239–253. [CrossRef]
3. Forner, A.; Ayuso, C.; Varela, M.; Rimola, J.; Hessheimer, A.J.; de Lope, C.R.; Reig, M.; Bianchi, L.; Llovet, J.M.; Bruix, J. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: Are response evaluation criteria in solid tumors reliable? Cancer 2009, 115, 616–623. [CrossRef] [PubMed]
4. Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A.; Wanders, J.; Kaplan, R.S.; Rubinstein, L.; Verweij, J.; Van Glabbeke, M.; van Oosterom, A.T.; Christian, M.C.; et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000, 92, 205–216. [CrossRef]
5. Miller, A.B.; Hoogstraten, B.; Staquet, M.; Winkler, A. Reporting results of cancer treatment. Cancer 1981, 47, 207–214. [CrossRef]
6. Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; Gwyther, S.; Mooney, M.; et al. New response evaluation criteria in solid tumors: Revised recist guideline (version 1.1). Eur. J. Cancer 2009, 45, 228–247. [CrossRef] [PubMed]
7. Wahl, R.L.; Jacene, H.; Kasamon, Y.; Lodge, M.A. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 2009, 50, S122–S150. [CrossRef] [PubMed]
8. Wolchok, J.D.; Hoos, A.; O’Day, S.; Weber, J.S.; Hamid, O.; Lebbe, C.; Maio, M.; Binder, M.; Bohnsack, O.; Nichol, G.; et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin. Cancer Res. 2009, 15, 7412–7420. [CrossRef]
9. Choi, H.; Charnsangavej, C.; Faria, S.C.; Macapinlac, H.A.; Burgess, M.A.; Patel, S.R.; Chen, L.L.; Podoloff, D.A.; Benjamin, R.S. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J. Clin. Oncol. 2007, 25, 1753–1759. [CrossRef] [PubMed]
10. Bruix, J.; Sherman, M.; Llovet, J.M.; Beaugrand, M.; Lencioni, R.; Burroughs, A.K.; Christensen, E.; Pagliaro, L.; Colombo, M.; Rodes, J.; et al. Clinical management of hepatocellular carcinoma. Conclusions of the barcelona-2000 easl conference. European association for the study of the liver. J. Hepatol. 2001, 35, 421–430. [CrossRef]
11. Lencioni, R.; Llovet, J.M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 2010, 30, 52–60. [CrossRef] [PubMed]
12. Kudo, M.; Kubo, S.; Takayasu, K.; Sakamoto, M.; Tanaka, M.; Ikai, I.; Furuse, J.; Nakamura, K.; Makuuchi, M.; Liver Cancer Study Group of Japan. Response evaluation criteria in cancer of the liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 revised version). Hepatol. Res. 2010, 40, 686–692. [CrossRef] [PubMed]
13. Kudo, M.; Han, K.H.; Kokudo, N.; Cheng, A.L.; Choi, B.I.; Furuse, J.; Izumi, N.; Park, J.W.; Poon, R.T.; Sakamoto, M. Liver cancer working group report. Jpn. J. Clin. Oncol. 2010, 40, i19–i27. [CrossRef] [PubMed]
14. Hamaoka, T.; Madewell, J.E.; Podoloff, D.A.; Hortobagyi, G.N.; Ueno, N.T. Bone imaging in metastatic breast cancer. J. Clin. Oncol. 2004, 22, 2942–2953. [CrossRef] [PubMed]
15. Macdonald, D.R.; Cascino, T.L.; Schold, S.C., Jr.; Cairncross, J.G. Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 1990, 8, 1277–1280. [PubMed]
16. Wen, P.Y.; Macdonald, D.R.; Reardon, D.A.; Cloughesy, T.F.; Sorensen, A.G.; Galanis, E.; Degroot, J.; Wick, W.; Gilbert, M.R.; Lassman, A.B.; et al. Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J. Clin. Oncol. 2010, 28, 1963–1972. [CrossRef] [PubMed]
17. Young, H.; Baum, R.; Cremerius, U.; Herholz, K.; Hoekstra, O.; Lammertsma, A.A.; Pruim, J.; Price, P.; European Organization for Research and Treatment of Cancer (EORTC) Pet Study Group. Measurement of clinical and subclinical tumor response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. Eur. J. Cancer 1999, 35, 1773–1782. [CrossRef]
18. Costelloe, C.M.; Chuang, H.H.; Madewell, J.E.; Ueno, N.T. Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J. Cancer 2010, 1, 80–92. [CrossRef] [PubMed]
19. Hamaoka, T.; Costelloe, C.M.; Madewell, J.E.; Liu, P.; Berry, D.A.; Islam, R.; Theriault, R.L.; Hortobagyi, G.N.; Ueno, N.T. Tumor response interpretation with new tumor response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br. J. Cancer 2010, 102, 651–657. [CrossRef] [PubMed]
20. Hayashi, N.; Costelloe, C.M.; Hamaoka, T.; Wei, C.; Niikura, N.; Theriault, R.L.; Hortobagyi, G.N.; Madewell, J.E.; Ueno, N.T. A prospective study of bone tumor response assessment in metastatic breast cancer. Clin. Breast Cancer 2013, 13, 24–30. [CrossRef] [PubMed]
21. Vassiliou, V.; Andreopoulos, D. Assessment of therapeutic response in patients with metastatic skeletal disease: Suggested modifications for the MDA response classification criteria. Br. J. Cancer 2010, 103, 925–926. [CrossRef] [PubMed]
22. Van der Veldt, A.A.; Meijerink, M.R.; van den Eertwegh, A.J.; Haanen, J.B.; Boven, E. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br. J. Cancer 2010, 102, 803–809. [CrossRef] [PubMed]
23. Stacchiotti, S.; Negri, T.; Palassini, E.; Conca, E.; Gronchi, A.; Morosi, C.; Messina, A.; Pastorino, U.; Pierotti, M.A.; Casali, P.G.; et al. Sunitinib malate and figitumumab in solitary fibrous tumor: Patterns and molecular bases of tumor response. Mol. Cancer Ther. 2010, 9, 1286–1297. [CrossRef] [PubMed]
24. Faivre, S.; Zappa, M.; Vilgrain, V.; Boucher, E.; Douillard, J.Y.; Lim, H.Y.; Kim, J.S.; Im, S.A.; Kang, Y.K.; Bouattour, M.; et al. Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib. Clin. Cancer Res. 2011, 17, 4504–4512. [CrossRef] [PubMed]
25. Prajapati, H.J.; Spivey, J.R.; Hanish, S.I.; El-Rayes, B.F.; Kauh, J.S.; Chen, Z.; Kim, H.S. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann. Oncol. 2013, 24, 965–973. [CrossRef] [PubMed]
26. Ziai, D.; Wagner, T.; El Badaoui, A.; Hitzel, A.; Woillard, J.B.; Melloni, B.; Monteil, J. Therapy response evaluation with FDG-PET/CT in small cell lung cancer: A prognostic and comparison study of the PERCIST and EORTC criteria. Cancer Imaging 2013, 13, 73–80. [CrossRef] [PubMed]
27. Hoos, A.; Eggermont, A.M.; Janetzki, S.; Hodi, F.S.; Ibrahim, R.; Anderson, A.; Humphrey, R.; Blumenstein, B.; Old, L.; Wolchok, J. Improved endpoints for cancer immunotherapy trials. J. Natl. Cancer Inst. 2010, 102, 1388–1397. [CrossRef] [PubMed]
28. Hoos, A.; Wolchok, J.D.; Humphrey, R.W.; Hodi, F.S. CCR 20th anniversary commentary: Immune-related response criteria—Capturing clinical activity in immuno-oncology. Clin. Cancer Res. 2015, 21, 4989–4991. [CrossRef]
29. Patel, S.P.; Woodman, S.E. Profile of ipilimumab and its role in the treatment of metastatic melanoma. Drug Des. Dev. Ther. 2011, 5, 489–495.
30. Hodi, F.S.; Hwu, W.J.; Kefford, R.; Weber, J.S.; Daud, A.; Hamid, O.; Patnaik, A.; Ribas, A.; Robert, C.; Gangadhar, T.C.; et al. Evaluation of immune-related response criteria and recist v1.1 in patients with advanced melanoma treated with pembrolizumab. J. Clin. Oncol. 2016, 34, 1510–1517. [CrossRef] [PubMed]
31. Pauwels, E.K.; Coumou, A.W.; Kostkiewicz, M.; Kairemo, K. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging in oncology: Initial staging and evaluation of cancer therapy. Med. Princ. Pract. 2013, 22, 427–437. [CrossRef] [PubMed]
32. Dos Anjos, R.F.; Dos Anjos, D.A.; Vieira, D.L.; Leite, A.F.; Figueiredo, P.T.; de Melo, N.S. Effectiveness of FDG-PET/CT for evaluating early response to induction chemotherapy in head and neck squamous cell carcinoma: A systematic review. Medicine 2016, 95, e4450. [CrossRef] [PubMed]
33. Subbiah, V.; Naing, A.; Brown, R.E.; Chen, H.; Doyle, L.; LoRusso, P.; Benjamin, R.; Anderson, P.; Kurzrock, R. Targeted morphoproteomic profiling of Ewing’s sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: Response/resistance signatures. PLoS ONE 2011, 6, e18424. [CrossRef]
34. Subbiah, V.; Murthy, R.; Anderson, P.M. [90Y]yttrium microspheres radioembolotherapy in desmoplastic small round cell tumor hepatic metastases. J. Clin. Oncol. 2011, 29, e292–e294. [CrossRef] [PubMed]
35. Subbiah, V.; Brown, R.E.; McGuire, M.F.; Buryanek, J.; Janku, F.; Younes, A.; Hong, D. A novel immunomodulatory molecularly targeted strategy for refractory hodgkin’s lymphoma. Oncotarget 2014, 5, 95–102. [CrossRef] [PubMed]
36. Schelhaas, S.; Held, A.; Wachsmuth, L.; Hermann, S.; Honess, D.J.; Heinzmann, K.; Smith, D.M.; Griffiths, J.R.; Faber, C.; Jacobs, A.H. Gemcitabine mechanism of action confounds early assessment of treatment response by 3’-deoxy-3’-[18F]fluorothymidine in preclinical models of lung cancer. Cancer Res. 2016, 76, 7096–7105. [CrossRef] [PubMed]
37. Subbiah, V.; Anderson, P.; Rohren, E. Alpha emitter radium 223 in high-risk osteosarcoma: First clinical evidence of response and blood-brain barrier penetration. JAMA Oncol. 2015, 1, 253–255. [CrossRef]
38. Hyun, O.J.; Luber, B.S.; Leal, J.P.; Wang, H.; Bolejack, V.; Schuetze, S.M.; Schwartz, L.H.; Helman, L.J.; Reinke, D.; Baker, L.H.; et al. Response to early treatment evaluated with 18F-FDG PET and PERCIST 1.0 predicts survival in patients with ewing sarcoma family of tumors treated with a monoclonal antibody to the insulinlike growth factor 1 receptor. J. Nucl. Med. 2016, 57, 735–740. [CrossRef] [PubMed]
39. O’Connor, J.P.; Aboagye, E.O.; Adams, J.E.; Aerts, H.J.; Barrington, S.F.; Beer, A.J.; Boellaard, R.; Bohndiek, S.E.; Brady, M.; Brown, G.; et al. Imaging biomarker roadmap for cancer studies. Nat. Rev. Clin. Oncol. 2016. [CrossRef] [PubMed]
40. Radford, J.A.; Cowan, R.A.; Flanagan, M.; Dunn, G.; Crowther, D.; Johnson, R.J.; Eddleston, B. The significance of residual mediastinal abnormality on the chest radiograph following treatment for hodgkin’s disease. J. Clin. Oncol. 1988, 6, 940–946. [PubMed]
41. Subbiah, V. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N. Engl. J. Med. 2008, 358, 743. [PubMed]
42. Subbiah, V.; Ly, U.K.; Khiyami, A.; O’Brien, T. Tissue is the issue-sarcoidosis following ABVD chemotherapy for Hodgkin’s lymphoma: A case report. J. Med. Case Rep. 2007, 1, 148. [CrossRef] [PubMed]
43. Gillies, R.J.; Kinahan, P.E.; Hricak, H. Radiomics: Images are more than pictures, they are data. Radiology 2016, 278, 563–577. [CrossRef] [PubMed]